key: cord-0715432-19ir2oyx
authors: Watashi, Koichi
title: Identifying and repurposing antiviral drugs against severe acute respiratory syndrome coronavirus 2 with in silico and in vitro approaches
date: 2020-11-20
journal: Biochem Biophys Res Commun
DOI: 10.1016/j.bbrc.2020.10.094
sha: e6005c19ed033debf64ebba8c9036a317aaa571e
doc_id: 715432
cord_uid: 19ir2oyx

Coronavirus infectious diseases 2019 (COVID-19), a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been a serious public health threat worldwide. So far, there are no drugs and vaccines whose efficacy has been well-proven. After the outbreak, there has been a massive search for anti-SARS-CoV-2 medications, focusing on approved drugs because repurposing approved drugs will take less time to reach clinical usage than new drugs. This article summarizes the studies using in silico and in vitro approaches to identify therapeutic candidates among approved drugs that target the SARS-CoV-2 life cycle.

Coronavirus infectious diseases 2019 originated in Wuhan, China in Dec 2019. With over 30 million confirmed infections and 1 million death as of the end of Sep 2020, COVID-19 has been causing considerable public health, social, and economic damage [1] [2] [3] . Developing vaccine and antiviral drugs against COVID-19 is a high priority.

The identification and development of new drugs generally require 10 to 20 years and high costs of around 800 million USD [4] . On the other hand, testing approved drugs may enable faster drug discovery and clinical use. Approved drugs' many advantages include commercial availability, proven safety and pharmacokinetics, and the reduced need for extensive preclinical or clinical testing for drug approval. The extensive focus on drug repurposing has led to a number of studies that have searched for candidates using different approaches, such as in silico, in vitro, cell culture, and in vivo models. This article summarizes the endeavors by researchers so far to identify anti-SARS-CoV-2 agents, especially those targeting the viral life cycle, from approved drugs.

In the early days after the outbreak of SARS-CoV-2, drug candidates were identified mainly by in silico docking. This virtual drug screening method targets the viral and host proteins essential for SARS-CoV-2 infection and replication. For example, the viral main protease (Mpro), papain-like protease (PLpro), and RNA-dependent RNA polymerase (RdRp) are essential for viral replication, and the viral Spike protein on the virion surface, angiotensin converting enzyme 2 (ACE2), a cellular receptor, and transmembrane protease, serine 2 (TMPRSS2), a cellular protease, are involved in viral entry into cells [5] .

Before the SARS-CoV-2 proteins' structure are solved, homology modeling based on other related coronaviruses' structural information can help delineate these proteins' structures. Using the homology modeling of Mpro, PLpro, RdRp, helicase, Spike, ACE2, and TMPRSS2, a compound database was screened to predict a series of drugs that bind to the target proteins, such as ribavirin to PLpro, montelukast to Mpro, remdesivir to RdRp and TMPRSS2, and hesperidin to Spike [6] . Another homology model-based study predicted that paritaprevir would bind to Mpro and furin, ritonavir to furin, and chloroquine to furin [7] .

The crystal structure of SARS-CoV-2 Mpro was firstly registered in the database on Feb 2020 (PDB: 6lu7) and later published by several groups [8] [9] [10] [11] . Jin et al. used the structural information for the virtual screening of over 10,000 compounds and identified six candidate compounds, such as ebselen, which was shown to inhibit SARS-CoV-2 propagation in Vero J o u r n a l P r e -p r o o f cell-based infection assay with a half maximal inhibitory concentration (IC 50 ) of 4.67 µM [8] .

Furthermore, the structural information of Mpro has enabled the broad use of molecular docking for virtual compound screening. Many papers report many approved drugs predicted to bind to Mpro, including ribavirin, telbivudine, zanamivir, indinavir, saquinavir, remdesivir, carfilzomib, eravacycline, disulfiram, captopril, ritonavir, viomycin, glecaprevir, maraviroc, telaprevir, boceprevir, argatroban, sitagliptin, vidarabine, lopinavir, tipranavir, raltegravir, daunorubicin, ergotamine, doxycycline, minocycline, cobicistat, simeprevir and pyronaridine [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] .

The first crystal structure of PLpro was registered in the database in April 2020 (PDB: 6W9C). The papers reporting the unliganded PLpro structure and the structure of PLpro in complex with its substrate, interferon-stimulated gene 15 (ISG15), were published in July and Sep 2020, respectively [25, 26] . In the virtual docking screenings based on PLpro's structure, phenformin, quercetin, ritonavir, and tiracizine had the highest docking scores among the FDA-approved drugs examined [27, 28] .

The structure of RdRp was reported by cryo-electron microscopy in April 2020 [29, 30] .

A structural analysis was performed to study the inhibition of RdRp by remdesivir's active metabolite, remdesivir-triphosphate [31, 32] . The cryo-electron microscopic structure of the SARS-CoV-2 polymerase complex consisting of nsp12 (RdRp), nsp7, and nsp8 was reported in May 2020 [33] . Virtual screening has selected many approved drugs that were anticipated to bind to RdRp, including nilotinib, saquinavir, tipranavir, lonafarnib, tegobuvir, olysio, cepharanthine, filibuvir, ornipressin, lypressin, examorelin, polymyxin B1, nacortocin, cistinexine, cisatracurium, bedoradrine, palbociclib, quinupristin, dactinomycin, sirolimus, cetrorelix, rifampin, nebivolol, .

The cryo-electron microscopic structure of the SARS-CoV-2 Spike protein was solved as a trimer in the prefusion complex in February and March 2020 [40, 41] . The crystal structures of the receptor-binding domain (RBD) of Spike protein in complex with its cellular receptor, ACE2, were also reported in March 2020 [42] [43] [44] . SARS-CoV-2 Spike's RBD had a more extensive binding interface and higher affinity with ACE2 than SARS-CoV Spike's RBD, suggesting that the SARS-CoV-2 Spike-receptor interaction can serve as a therapeutic target of antiviral agents. Spike protein's structure was also used for the in J o u r n a l P r e -p r o o f silico screening of approved drugs to identify Spike-binding candidates, such as phthalocyanine, hypericin, pirifibrate, talniflumate, cinacalcet, theaflavin, suramin, streptomycin, ciprofloxacin, glycyrrhizic acid, digitoxin, raltegravir, simeprevir, lumacaftor, pemirolast, sulfamethoxazole, valaciclovir, and pralatrexate [27, [45] [46] [47] [48] [49] [50] [51] . Eltrombopag, an immune thrombocytopenia drug, was identified to target the S2 domain of the Spike protein;

in vitro surface plasmon resonance analysis demonstrated that eltrombopag bound to the Spike protein weakly with µM order of K D value [52] .

The in silico screenings for drugs that target other viral and host proteins were also reported. Simeprevir, paritaprevir, and grazoprevir was estimated to bind to SARS-CoV-2 nsp13 helicase and nsp14 [53] . Eriodictyol was proposed to bind to the SARS-CoV-2 nsp10-nsp16 complex while lopinavir, eriodictyol, and pemirolast were selected as SARS-CoV-2 nsp3 binding compounds [54] .

On the other hand, neratinib, dacomitinib, and domatinostat as cathepsin-binding drugs, and lodoxamide, boceprevir, and aceneuramic acid as TMPRSS2-targeting drugs were reported [55] . Another report selected approved drugs that could bind to TMPRSS2, including tanogitran, radotinib, and nafamostat [56] . Virtual screening with ACE2 as the target identified compounds, including lividomycin, burixafor, and quisinostat [57] .

It is notable that, during in silico docking screenings, even when analyses used the same structural database and the same protein as a drug target, they often ended up identifying different compounds. Therefore, the activity of candidate compounds has to be confirmed in vitro, cell culture, or ideally in vivo experiments.

The virtually predicted activities of a drug against viral or host enzymes can be demonstrated by in vitro enzymatic assays. For example, an active SARS-CoV-2 RdRp composed of nsp12 and nsp8 could be expressed in Sf9 insect cells and purified [58] . [59, 60] . The in vitro assays are significant for demonstrating the mode of action of drugs; however, the recombinant protein purifications take longer than cell culture infection assays. Therefore, high-throughput drug screenings for SARS-CoV-2 have been performed mostly with cell culture infection assay rather than in vitro assays.

Evaluating and screening drugs can be performed using cell culture assays that support SARS-CoV-2 infection. SARS-CoV-2 infection can be reproduced in cell lines such as Vero, VeroE6, Vero-based cells overexpressing TMPRSS2, Caco2, Huh-7, and Calu-3 cells;

Vero and VeroE6 cells have been frequently used for evaluation of drugs [61] [62] [63] [64] [65] .

High-throughput screening is performed by infecting these cell lines with SARS-CoV-2, then detecting the viral RNA by real-time RT-PCR or viral proteins by immunofluorescence. In addition, a specific combination of cell lines and viral strains exhibits cytopathic effects, which is another marker of viral propagation useful for large-scale screening. Other virus-free cell models can be used to reproduce a part of the viral life cycle, such as virus entry, membrane fusion, and replication; these models can also be used for compound screening at a lower biosafety level [66, 67] . The drugs identified to inhibit SARS-CoV-2

infection/replication in cell culture assays were summarized in Table. 1.

The cell-based assays were also used to rapidly examine a small number of drugs that have been reported to inhibit the other related coronaviruses, such as SARS-CoV or other viruses. In the early days after the SARS-CoV-2 outbreak, this approach was used to identify remdesivir, chloroquine, hydroxychloroquine, and arbidol, which inhibited SARS-CoV-2 propagation with IC 50 of uM range or less using VeroE6 cells [65, 68, 69] .

Chloroquine, hydroxychloroquine, and arbidol were suggested to inhibit viral entry, whereas remdesivir was suggested to inhibit viral replication. On the other hand, the antiviral activity of ribavirin and favipiravir was found to be minimal. A known TMPRSS2 inhibitor, camostat, inhibited SARS-CoV-2 infection in Vero cells overexpressing TMPRSS2 [66] .

Other approved antiviral drugs, including ivermectin, lopinavir, emetine, homoharringtonine, auranofin, gemcitabine, lycorine, oxysophoridine, suramin, nafamostat, obatoclax, salinomycin, amodiaquine, nelfinavir, mycophenolic acid, umifenovir, berberine, cyclosporine A, atazanavir, and artemisinin, were shown to inhibit SARS-CoV-2 propagation [63, 64, 67, [70] [71] [72] [73] [74] [75] [76] [77] . Nelfinavir was also shown to inhibit SARS-CoV-2-induced membrane fusion in a virus-free cell model, using Vero cells overexpressing the Spike protein [78] . sulfadoxine, exemestane, dyclonine, and arbidol showed the highest anti-SARS-CoV-2 activities in Caco2 cells [82] . However, these reports demonstrated the antiviral activity of drugs without an in-depth analysis of their mechanism.

From a library of approved drugs, we identified nelfinavir and cepharanthine, which, with their submicromolar IC 50 , showed higher antiviral potential than remdesivir, chloroquine, and lopinavir in VeroE6 cells overexpressing TMPRSS2 [83] . In silico and in vitro assay combined with cell culture infection demonstrated that nelfinavir bound to SARS-CoV-2

protein Mpro and inhibited its enzymatic activity with an IC 50 equivalent to that observed in the cell-based infection assay, while cepharanthine was shown to inhibit virus-cell attachment, possibly blocking Spike protein's interaction with its cellular receptor ACE2.

Mathematical modeling predicted each of these two drugs, at the clinical drug concentration, will decrease the viral load; the combination treatment with both drugs will further shorten the time needed to achieve virus elimination.

A combination of in silico, in vitro, cell culture, and mathematical analysis would be useful to test anti-SARS-CoV-2 drug candidates after drug screening. Riva et al. provided another example with a screening of approximately 12,000 FDA-approved or clinical-stage drugs. They selected 21 drugs showing dose-dependent antiviral activity; most of these drugs were pre-approved compounds, such as those classified as PIKfyve inhibitor and cysteine protease inhibitors also included were clofazimide, astemizole, and remdesivir [84] .

They examined the expression level of possible host targets of hit compounds in human airway samples, and measured the enzymatic activity of viral proteases in vitro to predict the drug efficacy and mode of action. They also tested the candidate compounds' antiviral activities in induced pluripotent stem cell-derived human pneumocyte-like cells and a J o u r n a l P r e -p r o o f primary human lung explant model, which were more physiologically relevant models.

These models enabled them to identify a series of promising compounds, although all of the candidates are still in the developmental phase.

Drug candidates having anti-SARS-CoV-2 activity in cell culture assay have been identified, and some of them are in a clinical trial. However, many reports only showed the drugs' anti-SARS-CoV-2 activity without a detailed analysis of their mechanism. In the future, further mechanistic analysis and the drug resistance profile would be important for improving treatment outcomes. Also, it should be noted that the drug activities, especially those targeting cellular factors, can depend on the type of cells used in the assay. For example, host-targeting entry inhibitors, chloroquine and its derivatives and camostat, showed diverse antiviral activities in cell types with different expression levels of TMPRSS2 [85] . In line with this argument, examining drug activity in physiologically relevant cells is essential for prospecting in vivo antiviral efficacy. Human airway epithelial cells in an air-liquid interface culture [86] and human induced pluripotent stem cell-derived lung epithelial cells [87, 88] will provide more physiological relevance to the study of SARS-CoV-2

infections. In addition, human organoids of a variety of tissues such as lung, intestine, blood vessel, kidney, liver, and brain were reported to be susceptible to infection by SARS-CoV-2 or its pseudovirus [89] [90] [91] [92] [93] [94] [95] [96] .

So far, the animal models used for evaluating SARS-CoV-2 infection and the resultant diseases include Syrian hamster, ferrets, hACE2-transgenic mice, and nonhuman primates such as cynomolgus macaques and rhesus macaques [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] . On the other hand, the wild type mice cannot be infected with SARS-CoV-2 due to a lack of efficient interaction between the Spike protein and mouse ACE2; however, an adaptive strain of SARS-CoV-2 was generated that infects the wild type mice [109] [110] [111] .

These animal models have been shown to be useful for evaluating the efficacy of vaccine candidates and neutralizing antibodies [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] ; however, there are only a few examples that demonstrated the antiviral effect of drugs using these models. Remdesivir was examined in the rhesus macaque model. Although remdesivir did not reduce the viral load in the upper respiratory tract, it significantly decreased the virus infectious titer in the lower respiratory tract from 12 h after administration. The percentage of virus-negative in the lung lobe at seven days after infection was higher in remdesivir-treated animals than the untreated animals [121] . Remdesivir-treated animals also showed a low clinical score of respiratory disease and a reduction in lung damage, suggesting that remdesivir inhibits J o u r n a l P r e -p r o o f SARS-CoV-2 replication and prevents the progression of pneumonia in vivo. A commentary reported no significant antiviral effect of hydroxychloroquine in infected hamsters, cynomolgus macaques, or rhesus macaques, or in mice infected with mouse-adapted SARS-CoV-2, despite its anti-SARS-CoV-2 activity in cell culture [122] .

Mice infected with adapted SARS-CoV-2 strains were also used to evaluate chloroquine and chlorpromazine, which resulted in no apparent reduction in viral load but improvement of clinical symptoms [123] . The infection model using ferrets showed that treatment with lopinavir-ritonavir, hydroxychloroquine, or emtricitabine-tenofovir did not show an overall reduction in the viral load in nasal, stool, or respiratory tissues; however, these drugs lowered the clinical scores in ferrets infected with SARS-CoV-2 [124] . In contrast, azathioprine, an immunosuppressant, delayed viral clearance, and prolonged clinical symptoms. These papers show that changes in clinical symptoms are likely more visible than those in the viral load in these animal models after drug treatment. It would be demanded to develop or optimize infection animal models that can evaluate antiviral activity by measuring viral load with higher sensitivity.

The screening of approved drugs enables the rapid identification of drug candidates with lower costs. Many approved drugs have been identified to have anti-SARS-CoV-2 activity.

Given the urgent demand for COVID-19 drugs and the known adverse effect profile of approved drugs, some of the identified drugs were moved directly to clinical evaluation without detailed experimental analysis. More detailed analysis, including the mode of action and the drug resistance profile as well as the examination of drug efficacy with in vivo infection models, are needed to enable the effective treatment of SARS-CoV-2 infection over the long term.

The author would like to thank Enago for the English language review. The author's work was supported by the Japan Society for the Promotion of Science KAKENHI Grants J o u r n a l P r e -p r o o f

Clinical features of patients infected with 2019 novel coronavirus in

A pneumonia outbreak associated with a new coronavirus of probable bat origin

A Novel Coronavirus from Patients with Pneumonia in China

The cost of new drug discovery and development

Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19

Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

Whole Genome Analysis and Targeted Drug Discovery Using Computational Methods and High Throughput Screening Tools for Emerged Novel Coronavirus (2019-nCoV

Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors

Structural plasticity of SARS-CoV-2 3CL M(pro) active site cavity revealed by room temperature X-ray crystallography

Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors

Using integrated computational approaches to identify safe and rapid treatment for SARS-CoV-2

Computational insights into tetracyclines as inhibitors against SARS-CoV-2 M(pro) via combinatorial molecular simulation calculations

Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus

A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease

Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: Virtual screening, molecular docking, and molecular dynamics simulation study

In-silico drug repurposing and molecular dynamics puzzled out potential SARS-CoV-2 main protease inhibitors

Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease

In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing

FDA-approved thiol-reacting drugs that potentially bind into the SARS-CoV-2 main protease, essential for viral replication

Potential anti-viral activity of approved repurposed drug against main protease of SARS-CoV-2: an in silico based approach

Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy

Fast Identification of Possible Drug Treatment of Coronavirus Disease-19

COVID-19) through Computational Drug Repurposing Study

Deep Learning Based Drug Screening for Novel Coronavirus 2019-nCov

Crystal structure of SARS-CoV-2 papain-like protease

Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity

silico Drug Repurposing for COVID-19: Targeting SARS-CoV-2 Proteins through Docking and Consensus Ranking

Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease

Structure of the RNA-dependent RNA polymerase from COVID-19 virus

Structure of replicating SARS-CoV-2 polymerase

Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir

Structural and Biochemical Characterization of the nsp12-nsp7-nsp8 Core Polymerase Complex from SARS-CoV-2

SARS-CoV-2 RNA Dependent RNA polymerase (RdRp) -A drug repurposing study

Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic

Targeting SARS-CoV-2 Nsp12/Nsp8 interaction interface with approved and investigational drugs: an in silico structure-based approach

Siltberg-Liberles, Potential RNA-dependent RNA polymerase inhibitors as prospective therapeutics against SARS-CoV-2

A computational approach to drug repurposing against SARS-CoV-2 RNA dependent RNA polymerase (RdRp)

SARS-CoV-2 and SARS-CoV: Virtual screening of potential inhibitors targeting RNA-dependent RNA polymerase activity (NSP12)

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Structural basis of receptor recognition by SARS-CoV-2

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

Screening of Therapeutic Agents for COVID-19 Using Machine Learning and Ensemble Docking Studies

In silico screening of known small molecules to bind ACE2 specific RBD on Spike glycoprotein of SARS-CoV-2 for repurposing against COVID-19

Repurposing approved drugs as inhibitors of SARS-CoV-2 S-protein from molecular modeling and virtual screening

Identification of a druggable binding pocket in the spike protein reveals a key site for existing drugs potentially capable of combating Covid-19 infectivity

Targeting the SARS-CoV-2 spike glycoprotein prefusion conformation: virtual screening and molecular dynamics simulations applied to the identification of potential fusion inhibitors

An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors

In Silico Screening of Potential Spike Glycoprotein Inhibitors of SARS-CoV-2 with Drug Repurposing Strategy

Eltrombopag is a potential target for drug intervention in SARS-CoV-2 spike protein

In silico structure modelling of SARS-CoV-2 Nsp13 helicase and Nsp14 and repurposing of FDA approved antiviral drugs as dual inhibitors

In silico molecular docking analysis for repurposing therapeutics against multiple proteins from SARS-CoV-2

Potential clinical drugs as covalent inhibitors of the priming proteases of the spike protein of SARS-CoV-2

Structure-based drug repositioning over the human TMPRSS2 protease domain: search for chemical probes able to repress SARS-CoV-2 Spike protein cleavages

Prioritizing potential ACE2 inhibitors in the COVID-19 pandemic: Insights from a molecular mechanics-assisted structure-based virtual screening experiment

Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency

Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease

Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease

Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro

Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells

The FDA-approved gold drug auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells

Suramin Inhibits SARS-CoV-2 Infection in Cell Culture by Interfering with Early Steps of the Replication Cycle

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a

Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro

Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production

Potential Antiviral Options against SARS-CoV-2 Infection

Antiviral activities of J o u r n a l P r e -p r o o f mycophenolic acid and IMD-0354 against SARS-CoV-2

In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2

Gemcitabine, lycorine and oxysophoridine inhibit novel coronavirus (SARS-CoV-2) in cell culture

The anti-HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV-2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID-19 infections

Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model

Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs

Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system

In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication

Multidrug treatment with nelfinavir and cepharanthine against COVID-19, bioRxiv

Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing

Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2

Suthar, Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures

SARS-CoV-2 Infection of Pluripotent Stem Cell-Derived Human Lung Alveolar Type 2 Cells Elicits a Rapid Epithelial-Intrinsic Inflammatory Response

Human Induced Pluripotent Stem Cell-Derived Lung Epithelial System for SARS-CoV-2 Infection Modeling and Its Potential in Drug Repurposing

SARS-CoV-2 productively infects human gut enterocytes

Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2

SARS-CoV-2 targets neurons of 3D human brain organoids

Cholesterol 25-Hydroxylase inhibits SARS-CoV-2 and other coronaviruses by depleting membrane cholesterol

A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV

Tropism and Model Virus Infection in Human Cells and Organoids

Infection of Brain Organoids and 2D Cortical Neurons with SARS-CoV-2 Pseudovirus

TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes

Infection of bat and human intestinal organoids by SARS-CoV-2

The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice

CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies

Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development

Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling

Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human

Infection and Rapid Transmission of SARS-CoV-2 in Ferrets

Respiratory disease in rhesus macaques inoculated with SARS-CoV-2

SARS-CoV-2 is transmitted via contact and via the air between ferrets

Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a J o u r n a l P r e -p r o o f small animal model

Pathogenesis and transmission of SARS-CoV-2 in golden hamsters

A Mouse Model of SARS-CoV-2 Infection and Pathogenesis

A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures

Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy

A Thermostable mRNA Vaccine against COVID-19

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2

High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2

A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

Potently neutralizing and protective human antibodies against SARS-CoV-2

Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2

Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients

Broad anti-coronaviral activity of FDA approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo

J.U. Jung, Y.K. Choi, Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets, mBio 11 (2020) . 10.1128/mBio.01114-20. J o u r n a l P r e -p r o o f 

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☐ The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Please note that all Biochemical and Biophysical Research Communications authors are required to report the following potential conflicts of interest with each submission. If applicable to your manuscript, please provide the necessary declaration in the box above.(1) All third-party financial support for the work in the submitted manuscript.(2) All financial relationships with any entities that could be viewed as relevant to the general area of the submitted manuscript.(3) All sources of revenue with relevance to the submitted work who made payments to you, or to your institution on your behalf, in the 36 months prior to submission. (4) Any other interactions with the sponsor of outside of the submitted work should also be reported. (5) Any relevant patents or copyrights (planned, pending, or issued). (6) Any other relationships or affiliations that may be perceived by readers to have influenced, or give the appearance of potentially influencing, what you wrote in the submitted work. As a general guideline, it is usually better to disclose a relationship than not.